Testing a new eye drop in healthy volunteers
Part of Eyes & vision clinical trials.
This trial tests a new eye drop called PAN-90806 in healthy people to see if it is safe and how the body handles it. Participants will receive the eye drops and be closely monitored.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 50 years old.
- You need to be in good general health (no significant medical conditions).
- Your body mass index (BMI) should be between 19 and 25.
- Your vision (with glasses or contacts) must be good in at least one eye.
- You cannot have had any eye surgery or active eye infections.
- You must not be taking any medications (including over-the-counter) for 28 days before the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental eye drop (EYC-0305) for wet AMD, a common cause of vision loss in older adults. The goal is to see if it can slow or prevent further damage to central vision.
This trial tests a new eye drop called NT-101 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if the drops can improve vision and reduce fluid in the eye, possibly as a less invasive alternative to injections.
This study tests a new eye drop treatment for people with wet age-related macular degeneration (AMD) who have already been treated with standard injections. The goal is to see if this new treatment can help maintain or improve vision and reduce the need for injections.
This trial tests whether a new eye drop called BT01001 is safe for healthy adults. You may join if you have good overall and eye health, and do not use contact lenses or have chronic eye problems.
This study tests an experimental eye drop medication in healthy adults to see if it is safe and how the body handles it. It may help develop a new treatment for eye conditions.
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Hear when a new Wet Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.